Lamure, S.; Van Laethem, F.; De Verbizier, D.; Lozano, C.; Gehlkopf, E.; Tudesq, J.-J.; Serrand, C.; Benzaoui, M.; Kanouni, T.; Quintard, A.;
et al. Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy. Cancers 2021, 13, 4279.
https://doi.org/10.3390/cancers13174279
AMA Style
Lamure S, Van Laethem F, De Verbizier D, Lozano C, Gehlkopf E, Tudesq J-J, Serrand C, Benzaoui M, Kanouni T, Quintard A,
et al. Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy. Cancers. 2021; 13(17):4279.
https://doi.org/10.3390/cancers13174279
Chicago/Turabian Style
Lamure, Sylvain, François Van Laethem, Delphine De Verbizier, Claire Lozano, Eve Gehlkopf, Jean-Jacques Tudesq, Chris Serrand, Mehdi Benzaoui, Tarik Kanouni, Adeline Quintard,
and et al. 2021. "Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy" Cancers 13, no. 17: 4279.
https://doi.org/10.3390/cancers13174279
APA Style
Lamure, S., Van Laethem, F., De Verbizier, D., Lozano, C., Gehlkopf, E., Tudesq, J.-J., Serrand, C., Benzaoui, M., Kanouni, T., Quintard, A., De Vos, J., Tchernonog, E., Platon, L., Ayrignac, X., Ceballos, P., Sirvent, A., François, M., Guedon, H., Quittet, P.,
... Cartron, G.
(2021). Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy. Cancers, 13(17), 4279.
https://doi.org/10.3390/cancers13174279